TrovaGene, Inc. (TROV) Sets New 1-Year Low at $0.60
TrovaGene, Inc. (NASDAQ:TROV) hit a new 52-week low on Tuesday . The company traded as low as $0.60 and last traded at $0.60, with a volume of 268331 shares changing hands. The stock had previously closed at $0.63.
TROV has been the topic of a number of analyst reports. Maxim Group set a $4.00 price objective on TrovaGene and gave the company a “buy” rating in a report on Wednesday, October 18th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of TrovaGene in a report on Tuesday, August 8th. Finally, lowered TrovaGene from a “buy” rating to a “hold” rating in a report on Wednesday, November 15th.
TrovaGene (NASDAQ:TROV) last announced its quarterly earnings results on Thursday, November 9th. The medical research company reported ($0.12) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.14) by $0.02. The business had revenue of $0.12 million for the quarter. TrovaGene had a negative return on equity of 259.94% and a negative net margin of 7,960.05%.
Institutional investors have recently modified their holdings of the stock. LMR Partners LLP acquired a new position in shares of TrovaGene during the 2nd quarter worth approximately $151,000. Susquehanna International Group LLP raised its position in shares of TrovaGene by 2,781.0% during the 2nd quarter. Susquehanna International Group LLP now owns 138,031 shares of the medical research company’s stock worth $174,000 after purchasing an additional 133,240 shares during the last quarter. KCG Holdings Inc. raised its position in shares of TrovaGene by 560.1% during the 1st quarter. KCG Holdings Inc. now owns 210,301 shares of the medical research company’s stock worth $242,000 after purchasing an additional 178,440 shares during the last quarter. Finally, Goldman Sachs Group Inc. raised its position in shares of TrovaGene by 1,079.5% during the 2nd quarter. Goldman Sachs Group Inc. now owns 278,186 shares of the medical research company’s stock worth $351,000 after purchasing an additional 254,601 shares during the last quarter. Hedge funds and other institutional investors own 8.67% of the company’s stock.
Trovagene, Inc is a clinical-stage, precision medicine oncology therapeutics company. The Company’s lead drug candidate, PCM-075, is a Polo-like Kinase 1 (PLK1) selective adenosine triphosphate (ATP) competitive inhibitor. PCM-075 has shown preclinical antitumor activity as a single agent and in synergy combinations with more than ten different chemotherapeutics and targeted therapies, such as Zytiga (abiraterone acetate), Beleodaq (belinostat), Quizartinib (AC220), a development stage FLT3 inhibitor, and Velcade (bortezomib) in Acute Myeloid Leukemia (AML), metastatic Castration-Resistant Prostate Cancer (mCRPC) and other liquid and solid tumor cancers.
Receive News & Ratings for TrovaGene Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TrovaGene Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.